Roche Spanish plant becomes eighth solid dose site for Recipharm

By Dan Stanton contact

- Last updated on GMT

Image: GettyImages/PeterHermesFurian
Image: GettyImages/PeterHermesFurian
Recipharm has acquired a Spanish manufacturing plant and signed a supply deal with former owner Roche for a range of solid dose products worth €35m a year.

The contract development and manufacturing organisation (CDMO) has added the Leganés, Spain solid dose manufacturing plant to its network after coming to an agreement with former owner Roche.

While financial details have not been divulged, a long-term contract agreement between the firms will add approximately €35m ($42m) to Recipharm’s annual sales – equating to more than 6% of the CDMO’s total revenue – from the manufacture of a range of solid dose products from the facility for Roche.

According to Recipharm CEO Thomas Eldered, solid dose formulation was already the firm’s largest business segment before the acquisition but with the Leganés facility the firm will now operate eight solid dose facilities.

“Our ambition is to continue offer competitive services in this area,”​ he told in-Pharmatechnologist.

The added facility will also offer opportunity for collaboration with Recipharm’s facility near Barcelona, Spain.

Eldered added Recipharm – which has been aggressive on the M&A front after going public in 2014 (see here​, here​ and here​, for example) – will continue to look for expansion opportunities.

“We have a pretty full range service offering but we are looking for some further niche technologies. We are continuously evaluating additions that would be beneficial for our customers.”


The Leganés site, located near Madrid, was one of a number put up for sale by Roche in November 2015​ as part of a plan to reduce its small molecule manufacturing footprint.

In June 2016​, Greek CDMO Famar struck a deal with Roche to buy the plant but this subsequently fell through.

Earlier this month​, Italian CMO Delpharm completed its acquisition of Roche’s solid and liquid forms manufacturing facility in Milan/Segrate, Italy and – like Recipharm today – inked a supply contract with the Swiss pharma giant.

Other sites Roche earmarked in the restructure included   an API production plant in Florence, South Carolina sold to Patheon last year​, and a site in Clarecastle, Ireland​ which is being shuttered.

Related news

Show more

Related products

show more

Roquette Oral Dose Case Study - Part IV

Roquette Oral Dose Case Study - Part IV

Roquette Pharma Solutions | 04-Dec-2017 | Case Study

Download the latest Roquette case study and learn more on how PEARLITOL® Flash mannitol and starch compound offers inert stability, fast disintegration...

Roquette Oral Dose Case Study - Part III

Roquette Oral Dose Case Study - Part III

Roquette Pharma Solutions | 27-Nov-2017 | Case Study

Download the Case Study to find out how Roquette’s SweetPearl® P 300 DC maltitol technology makes an effervescent tablet solution attractive and palatable...

Roquette Oral Dose Case Study - Part II

Roquette Oral Dose Case Study - Part II

Roquette Pharma Solutions | 06-Nov-2017 | Case Study

Download the case study and learn more on how Roquette’s taste masking technology KLEPTOSE® Linecaps (KL) allows the delivery of an efficient taste masking...

The Solid Dose, Latest News from Colorcon

The Solid Dose, Latest News from Colorcon

Colorcon Inc. | 06-Nov-2017 | Data Sheet

With a commitment to serve customers through product innovation and technical excellence, Colorcon's Solid Dose newsletter brings you the latest insight...

Related suppliers